Patents by Inventor Donald Wilton

Donald Wilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
    Publication number: 20180155723
    Abstract: Provided are oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions including said oligonucleotides, kits including the compositions, and uses thereof. In particular, the subject matter provides compositions of oligonucleotides useful in methods for suppressing exon skipping optionally in combination with additional CFTR therapeutics.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 7, 2018
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Batsheva KEREM, Michal TUR SINAI, Loren PRICE, Stephen Donald WILTON, Sue FLETCHER
  • Agents useful in treating facioscapulohumeral muscular dystrophy
    Patent number: 9988628
    Abstract: The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: June 5, 2018
    Assignee: UNIVERSITE DE MONS
    Inventors: Alexandra Belayew, Frederique Coppee, Celine Vanderplanck, Stephen Donald Wilton, Eugenie Ansseau
  • Multiple Sclerosis Treatment
    Publication number: 20180104273
    Abstract: An antisense oligomer capabfe of binding to a selected target on the ITGA4 gene transcript to modify pre-mRNA splicing in an ITGA4 gene transcript or part thereof.
    Type: Application
    Filed: May 10, 2016
    Publication date: April 19, 2018
    Inventors: Stephen Donald Wilton, Sue Fletcher, May Aung-Htut
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20180051282
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: March 23, 2017
    Publication date: February 22, 2018
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20180002697
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • Antisense molecules and methods for treating pathologies
    Patent number: 9758783
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 12, 2017
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9605262
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 28, 2017
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE OLIGOMERS AND METHODS FOR TREATING SMN-RELATED PATHOLOGIES
    Publication number: 20170051277
    Abstract: An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.
    Type: Application
    Filed: September 12, 2014
    Publication date: February 23, 2017
    Inventors: Stephen Donald Wilton, Sue Fletcher, Loren Louise Price, Chalermchai Mitrpant
  • AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    Publication number: 20170029814
    Abstract: The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents.
    Type: Application
    Filed: February 18, 2016
    Publication date: February 2, 2017
    Inventors: Alexandra Belayew, Frederique Coppee, Celine Vanderplanck, Stephen Donald Wilton, Eugenie Ansseau
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20170009233
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 12, 2017
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20170009234
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 12, 2017
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9447415
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: September 20, 2016
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9441229
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 13, 2016
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9422555
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 23, 2016
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
    Publication number: 20160208264
    Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.
    Type: Application
    Filed: September 5, 2014
    Publication date: July 21, 2016
    Inventors: Stephen Donald Wilton, Sue Fletcher, Gunnar James Hanson, Richard Keith Bestwick
  • ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
    Publication number: 20160177301
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Application
    Filed: November 18, 2015
    Publication date: June 23, 2016
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 9249416
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 2, 2016
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20160002635
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20160002631
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20160002632
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey